Anti-Human CTGF Recombinant Antibody (Pamrevlumab) (CAT#: TAB-443CQ)

Recombinant monoclonal antibody to CTGF. Pamrevlumab is a human monoclonal antibody that can be potentially used in the treatment of Duchenne muscular dystrophy, Hepatic fibrosis, Idiopathic pulmonary fibrosis, Pancreatic cancer. It inhibits connective tissue growth factor (CTGF).


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Pharmacokinetic and pharmacodynamic profile of gemcitabine in KPC mice; error bars represent standard error of the mean (SEM).

Figure 1 Pharmacokinetic and pharmacodynamic profile of gemcitabine in KPC mice; error bars represent standard error of the mean (SEM).

(A) Pharmacokinetic profile of native (2′,2′-difluorodeoxycytidine; dFdC) and inactivated (2′,2′-difluorodeoxyuridine; dFdU) gemcitabine metabolites in plasma of KPC mice (n = 38 in total) following a single i.p. injection of 100 mg/kg dFdC. The following time points were analyzed: 0 h (n = 5), 1 h (n = 7), 2 h (n = 7), 4 h (n = 7), 6 h (n = 7), and 10 h (n = 5). (B) Pharmacokinetic profile of native (dFdC), inactivated (dFdU), and active (2′,2′-difluorodeoxycytidine-5′-triphosphate; dFdCTP) gemcitabine metabolites in tumor biopsies of KPC mice (n = 65 in total) corresponding to the same samples displayed in A for 0 h (n = 4), 1 h (n = 21), 2 h (n = 15), 4 h (n = 19), 6 h (n = 7), and 10 h (n = 5). (C) Pharmacodynamic profile of cleaved caspase 3 and phosphohistone H3 immunohistochemistry in tumor samples from KPC mice (n = 65 in total) following a single i.p. injection of 100 mg/kg dFdC. (D) Quantification of proliferation (PH3) and apoptosis (CC3) in small intestinal cells following a single dose of 100 mg/kg i.p. of gemcitabine. Each time point represents ≥5 mice. (E) Preenrollment tumor volumes of the 9-d shortterm study (n ≥ 6 each cohort) showing no significant differences before enrollment. (F) Schematic of the short-term 9-d trial for the combination therapy of FG-3019 and gemcitabine in tumor-bearing KPC mice.

Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., ... & Tuveson, D. A. (2013). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences, 110(30), 12325-12330.

Figure 2 CTGF is present in KPC tumors and plasma.

Figure 2 CTGF is present in KPC tumors and plasma.

Representative CTGF immunohistochemistry in normal pancreas (NP) tissue (n = 3; Top Left), pancreatic intraepithelial neoplasia (PanIN) (n = 6; Top Right), and a murine pancreatic cancer specimen (n = 11) with stromal (Middle) and tumor cell (Bottom) expression patterns.

Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., ... & Tuveson, D. A. (2013). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences, 110(30), 12325-12330.

Figure 3 CTGF is present in KPC tumors and plasma.

Figure 3 CTGF is present in KPC tumors and plasma.

Western blot analysis of CTGF, α-SMA, and E-cadherin in primary murine tumor and cancer-associated fibroblast cell lines.

Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., ... & Tuveson, D. A. (2013). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences, 110(30), 12325-12330.

Figure 4 CTGF is present in KPC tumors and plasma.

Figure 4 CTGF is present in KPC tumors and plasma.

Plasma of WT (n = 7) and tumor-bearing KPC mice (n = 30; P < 0.0001; LLOQ, 9.4 ng/mL) by ELISA.

Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., ... & Tuveson, D. A. (2013). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences, 110(30), 12325-12330.

Figure 5 FG-3019 induces neoplastic apoptosis but does not alter tumor stroma, vasculature, and gemcitabine pharmacology over a 9-d course.

Figure 5 FG-3019 induces neoplastic apoptosis but does not alter tumor stroma, vasculature, and gemcitabine pharmacology over a 9-d course.

Representative coimmunofluorescence images of DAPI (blue), E-cadherin (green), and CC3 (orange) in each of the 9 d-treated cohorts.

Neesse, A., Frese, K. K., Bapiro, T. E., Nakagawa, T., Sternlicht, M. D., Seeley, T. W., ... & Tuveson, D. A. (2013). CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences, 110(30), 12325-12330.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG1, κ
  • Specificity
  • Human CTGF
  • Species Reactivity
  • Human
  • Applications
  • ELISA, IHC, FC, IP, IF, Inhib
  • Conjugate
  • Unconjugated
  • CAS
  • 946415-13-0
  • Generic Name
  • Pamrevlumab
  • UNII
  • QS5F6VTS0O
  • Related Disease
  • Duchenne muscular dystrophy, Hepatic fibrosis, Idiopathic pulmonary fibrosis, Pancreatic cancer

Product Property

  • Purity
  • > 95% as determined by SDS-PAGE
  • Storage
  • Store at -20°C for long-term storage. Avoid freeze/thaw cycles.

Applications

  • Application Notes
  • The CTGF antibody has been reported in applications of PK , IHC, WB, ELISA, IF.

Target

  • Alternative Names
  • CTGF; connective tissue growth factor; CCN2; NOV2; HCS24; IGFBP8; IBP-8; IGFBP-8; CCN family member 2; IGF-binding protein 8; hypertrophic chondrocyte-specific protein 24; insulin-like growth factor-binding protein 8

Related Resources

  • Biosimilar Overview
Please refer to Pamrevlumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Pamrevlumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Pamrevlumab"

Afuco™ Anti-CTGF ADCC Recombinant Antibody (Pamrevlumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CTGF. Pamrevlumab is a human monoclonal antibody that can be potentially used in the treatment of Duchenne muscular dystrophy, Hepatic fibrosis, Idiopathic pulmonary fibrosis, Pancreatic cancer. It inhibits connective tissue growth factor (CTGF).

See other products for "CTGF"

Recombinant Antibody

Fc Glycosylation

CAT Product Name Application Type
Gly-119LC Recombinant Anti-Human CTGF Antibody (Fc glycosylation) ELISA Human antibody

scFv Fragment Antibody

CAT Product Name Application Type
HPAB-0181-YC-S(P) Human Anti-CTGF Recombinant Antibody; scFv Fragment (HPAB-0181-YC-S(P)) ELISA, FuncS Human scFv

Fab Fragment Antibody

CAT Product Name Application Type
HPAB-0181-YC-F(E) Human Anti-CTGF Recombinant Antibody; Fab Fragment (HPAB-0181-YC-F(E)) ELISA, FuncS Human Fab

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-443CQ Afuco™ Anti-CTGF ADCC Recombinant Antibody (Pamrevlumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, Inhib ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-443CQ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare